No study has examined ketamine users’ psychiatric morbidity using structured diagnostic instruments. The aim of this study was thus to determine the psychiatric comorbidity of community-based ketamine users using the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), Axis I Disorders (SCID).
Methods
A convenience sample of 200 frequent ketamine users was recruited from community organizations in Hong Kong. Participants were screened with the Severity of Dependence Scale (SDS), Beck Depression Inventory (BDI), Anxiety subscale of the Hospital Anxiety Depression Scale (HADSA), and SCID psychotic symptoms. Those who scored above the threshold (cutoff point of 8/9 on the BDI and 4/5 on HADSA) or displayed evidence of psychotic symptoms were referred for a structured clinical interview conducted by a psychiatrist.
Results
One hundred and seventy participants scored above the cutoff point on 1 or more of the scales, and 115 participants attended the SCID interview. Fifty-one of these 115 participants received a psychiatric diagnosis of 1 or more comorbidities for the month preceding the interview. Mood disorders accounted for 80.4% of the diagnoses, anxiety disorders for 33.3%, and psychotic disorders for 7.8%.
Conclusions
Female gender and history of psychiatric/psychological clinic attendance were significantly associated with comorbid psychiatric disorders, whereas ketamine dependence had a borderline association.
TamannaS, GeraciSA. Major sleep disorders among women: (women's health series). South Med J. 2013;106:470–478.
2.
Central Registry of Drug Abuse. Drug Abusers for 2002–2011 by Age by Sex by Common Type of Drugs. Hong Kong: Hong Kong Narcotics Division; 2012.
3.
ElwoodP, HackM, PickeringJ, HugheJ, GallacherJ. Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. J Epidemiol Community Health. 2006;90:69–73.
4.
WinstockAR, MitchesonL, GillattDA, CottrellAM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012;110:1762–1766.
5.
JohnstonLD, O'MalleyPM, MiechRA, BachmanJG, SchulenbergJE. Monitoring the future: national survey results on drug use 1975–2013. Available at: http://www.monitoringthefuture.org. Accessed April 3, 2014.
6.
JohnstonLD, O'MalleyPM, BachmanJG, SchulenbergJE. Monitoring the future: national survey results on drug use 1975–2012. Available at: http://www.monitoringthefuture.org. Accessed August 17, 2013.
7.
EcclestonC, CrombezG. Pain demands attention: a cognitive-affective model of the interruptive function of pain. Psychol Bull.1999;125:356–366.
8.
LanghorneP, StottDJ, RobertsonL, . Medical complications after stroke: a multicenter study. Stroke. 2000;31:12223–11229.
9.
MayerG, JennumP, RiemannD, DauvilliersY. Insomnia in central neurologic diseases—occurrence and management. Sleep Med Rev.2011;15:369–378.
10.
National Stroke Foundation. Pain Management After Stroke. Melbourne, Australia, National Stroke Foundation National Office; 2012.
11.
MorganC, CurranHV. Ketamine use: a review. Addiction. 2011;107:27–38.
12.
Abi-SaabWM, D'souzaDC, MoghaddamB, KrystalJH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry. 1998;31(Suppl 2):104–109.
13.
AdlerCM, MalhotraAK, ElmanI, . Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry. 1999;156:1646–1649.
14.
KrystalJH, KarperLP, SeibylJP, . Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214.
15.
KrystalJH, BelgerA, D'souzaDC, AnandA, . Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology. 1999;21:S143–S157.
16.
KrystalJH, D'souzaDC, PetrakisIL, . NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry. 1999;7:125–143.
17.
KrystalJH, PerryEBJr, GueorguievaR, . Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62:985–994.
18.
LahtiAC, HolcombHH, GaoX, TammingaCA. NMDA sensitive glutamate antagonism: a human model for psychosis. Neuropsychopharmacology. 1999;21:S158–S169.
19.
LahtiAC, WeilerMA, Tamara MichaelidisBA, ParwaniA, TammingaCA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455–467.
20.
MalhotraAK, PinalsDA, WeingartnerH, . NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14:301–307.
21.
NewcomerJW, FarberNB, Jevtovic-TodorovicV, . Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–118.
22.
KrystalJH, KarperLP, BennettA, . Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl). 1998;135:213–229.
23.
KrystalJH, PetrakisIL, KrupitskyE, SchutzC, TrevisanL, D'souzaDC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci. 2003;1003:176–184.
24.
NovyDM, NelsonDV, FrancisDJ, TurkDC. Perspectives of chronic pain: an evaluative comparison of restrictive and comprehensive models. Psychol Bull. 1995;118:238–247.
25.
ZarateCAJr, SinghJB, CarlsonPJ, . A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
26.
Aan Het RotM, CollinsKA, MurroughJW, . Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–145.
27.
CurranHV, MorganCJ. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction. 2000;95:575–590.
28.
MorganCJ, MonaghanL, CurranHV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction. 2004;99:1450–1461.
29.
MorganCJ, MuetzelfeldtL, CurranHV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105:121–133.
30.
MorganCJ, DuffinS, HuntS, MonaghanL, MasonO, CurranHV. Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis (‘skunk’) or on cocaine. Pharmacopsychiatry. 2012;45:269–274.
31.
TangA, LiangHJ, UngvariGS, TangWK. Referral patterns and clinical characteristics of subjects referred to substance abuse clinic of a regional hospital in Hong Kong. East Asian Arch Psychiatry. 2011;21:22–27.
32.
TangA, CheungRY, LiangHJ, UngvariGS, TangWK. Psychiatric morbidity at a female residential drug treatment centre in Hong Kong. East Asian Arch Psychiatry. 2011;21:28–31.
33.
MerikangasKR, MehtaRL, MolnarBE, . Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;28:893–907.
34.
RegierDA, FarmerME, RaeDS, . Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiological Catchment Area study. JAMA. 1990;264:2511–2518.
35.
GossopM, DarkeS, GriffithsP, . The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607–614.
36.
ShekDT. Reliability and factorial structure of the Chinese version of the Beck Depression Inventory. J Clin Psychol. 1990;46:35–43.
37.
LeeDT, YipAS, ChiuHF, LeungTY, ChungTK. Screening for postnatal depression: are specific instruments mandatory? J Affect Disord. 2001;63:233–238.
38.
LeungCM, HoS, KanCS, HungCH, ChenCN. Evaluation of the Chinese version of the Hospital Anxiety and Depression Scale: a cross-cultural perspective. Int J Psychosom. 1993;40:29–34.
39.
BuneviciusR, PeceliunieneJ, MickuvieneN, BuneviciusA, PopV, GirdlerS. Mood and thyroid immunity assessed by ultrasonographic imaging in a primary health care. J Affect Disord. 2007;97:85–90.
40.
SoE, KamI, LeungCM, PanA, LamL.The Chinese-bilingual SCID-I/P Project: stage 2—reliability for anxiety disorders, adjustment disorders, and “no diagnosis”. Hong Kong J Psychiatry. 2003;13:19–25.
41.
SoE, KamI, LeungCM, LiuZ, FongS. The Chinese-bilingual SCID-I/P Project: stage 1—reliability for mood disorders and schizophrenia. Hong Kong J Psychiatry. 2003;13:7–18.
42.
RichterP, WernerJ, HeerleinA, KrausA, SauerH. On the validity of the beck depression inventory. A review. Psychopathology. 1998;31:160–168.
43.
CharneyDA, ParaherakisAM, NegreteJC, GillKJ. The impact of depression on the outcome of addictions treatment. J Subst Abuse Treat. 1998;15:123–130.
44.
CurranGM, KirchnerJE, WorleyM, RookeyC, BoothBM. Depressive symptomatology and early attrition from intensive outpatient substance use treatment. J Behav Health Serv Res. 2002;29:138–143.
CorlettPR, HoneyGD, KrystalJH, FletcherPC. Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology. 2011;36:294–315.
49.
DavisL, UezatoA, NewellJM, FrazierE. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21:14–18.
50.
TortajadaS, HerreroMJ, Domingo-SalvanyA, . Psychiatric morbidity among cocaine and heroin users in the community. Adicciones. 2012;24:201–210.
51.
WuLT, GersingK, BurchettB, WoodyGE, BlazeDG. Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database. J Psychiatr Res.2011;45:1453–1462.
52.
OhayonMM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev.2002;6:97–111.
53.
SzymkowiczSM, FinneganN, DaleRM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord. 2013;147:416–420.
54.
KittelbergerK, HurEE, SazegarS, KeshavanV, KocsisB.Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct Funct. 2012;217:395–409.
55.
MoghaddamB, AdamsB, VermaA, DalyD. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–2927.
56.
NarendranR, FrankleWG, KeefeR, . Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005;162:2352–2359.
LiaoY, TangJ, FornitoA, . Alterations in regional homogeneity of resting-state brain activity in ketamine addicts. Neurosci Lett. 2012;522:36–40.
59.
LiaoY, TangJ, MaM, . Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain. 2010;133:2115–2122.
60.
MorganCJ, CurranHV. Ketamine use: a review. Addiction. 2012;107:27–38.
61.
JansenK.Ketamine: Dreams and Realities. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies; 2004: 244.
62.
RothmanRB, BaumannMH, DerschCM, . Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39:32–41.
63.
AraosP, Vergara-MoraguesE, PedrazM, . Psychopathological comorbidity in cocaine users in outpatient treatment. Adicciones. 2014;26:15–26.
64.
ChahuaM, SordoL, MolistG, . Depression in young regular cocaine users recruited in the community. Gac Sanit. 2014;28:155–159.
65.
RofaelHZ, Abdel-RahmanMS. The role of ketamine on plasma cocaine pharmacokinetics in rat. Toxicol Lett. 2002;129:167–176.
66.
MadhavanA, ArgilliE, BonciA, WhistlerJL. Loss of D2 dopamine receptor function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental area. J Neurosci. 2013;33:12329–12336.
67.
WakabayashiKT, KiyatkinEA. Rapid changes in extracellular glutamate induced by natural arousing stimuli and intravenous cocaine in the nucleus accumbens shell and core. J Neurophysiol. 2012;108:285–299.
68.
ShrivastavaA, JohnstonM, TerpstraK, BureauY. Cannabis and psychosis: neurobiology. Indian J Psychiatry. 2014;56:8–16.
HirotaK, LambertDG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77:441–444.
71.
BushlinI, RozenfeldR, DeviLA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol. 2010;10:80–86.
72.
FeigenbaumJJ, BergmannF, RichmondSA, . Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proc Natl Acad Sci U S A. 1989;86:9584–9587.
73.
GrantBF, StinsonFS, DawsonDA, . Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–816.
74.
BijlRV, De GraafR, RavelliA, SmitF, VolleberghWA. Gender and age specific first incidence of DSM-III-R psychiatric disorders in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 2002;37:372–379.
75.
KolltveitS, Lange-NielsenII, ThabetAA, . Risk factors for PTSD, anxiety, and depression among adolescents in gaza. J Trauma Stress. 2012;25:164–170.
76.
De GraafR, BijlRV, SmitF, VolleberghWA, SpijkerJ. Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands mental health survey and incidence study. Am J Psychiatry. 2002;159:620–629.
77.
ShrierLA, HarrisSK, KurlandM, KnightJR. Substance use problems and associated psychiatric symptoms among adolescents in primary care. Pediatrics. 2003;111:e699–e705.
78.
ChenLY, CrumRM, MartinsSS, KaufmannCN, StrainEC, MojtabaiR. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv. 2013;64:863–870.
79.
UrbanoskiKA, RushBR, WildTC, BassaniDG, CastelS. Use of mental health care services by Canadians with co-occurring substance dependence and mental disorders. Psychiatr Serv. 2007;58:962–969.
